Applied Therapeutics, Inc. (APLT): Price and Financial Metrics

Applied Therapeutics, Inc. (APLT): $2.42

0.31 (+14.69%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

APLT Price/Volume Stats

Current price $2.42 52-week high $3.11
Prev. close $2.11 52-week low $0.70
Day low $2.09 Volume 790,000
Day high $2.45 Avg. volume 521,192
50-day MA $2.32 Dividend yield N/A
200-day MA $1.58 Market Cap 186.89M

APLT Stock Price Chart Interactive Chart >

APLT POWR Grades

  • Growth is the dimension where APLT ranks best; there it ranks ahead of 79.4% of US stocks.
  • The strongest trend for APLT is in Quality, which has been heading down over the past 177 days.
  • APLT ranks lowest in Stability; there it ranks in the 2nd percentile.

APLT Stock Summary

  • APPLIED THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.32% of US listed stocks.
  • For APLT, its debt to operating expenses ratio is greater than that reported by merely 4.64% of US equities we're observing.
  • APLT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 2.23% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to APPLIED THERAPEUTICS INC are FGEN, CTMX, AGEN, NVAX, and CRDF.
  • APLT's SEC filings can be seen here. And to visit APPLIED THERAPEUTICS INC's official web site, go to www.appliedtherapeutics.com.

APLT Valuation Summary

  • APLT's price/sales ratio is 14; this is 723.53% higher than that of the median Healthcare stock.
  • Over the past 54 months, APLT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for APLT.

Stock Date P/S P/B P/E EV/EBIT
APLT 2023-11-03 14.0 -34.5 -2.0 -1.6
APLT 2023-11-02 13.7 -33.6 -2.0 -1.5
APLT 2023-11-01 13.7 -33.8 -2.0 -1.5
APLT 2023-10-31 14.2 -35.0 -2.1 -1.6
APLT 2023-10-30 14.8 -36.4 -2.2 -1.7
APLT 2023-10-27 15.5 -38.0 -2.3 -1.8

APLT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • APLT has a Quality Grade of D, ranking ahead of 18.8% of graded US stocks.
  • APLT's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows APLT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -2.346
2021-03-31 0 NA -2.452
2020-12-31 0 NA -2.024
2020-09-30 0 NA -2.007
2020-06-30 0 NA -2.036
2020-03-31 0 NA -1.946

APLT Price Target

For more insight on analysts targets of APLT, see our APLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $42.83 Average Broker Recommendation 1.5 (Moderate Buy)

Applied Therapeutics, Inc. (APLT) Company Bio


Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY


APLT Latest News Stream


Event/Time News Detail
Loading, please wait...

APLT Latest Social Stream


Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about APPLIED THERAPEUTICS INC that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Applied Therapeutics Inc (APLT) Reports Q3 2023 Financial Results Amidst Upcoming Clinical ...

Regulatory Submissions and Phase 3 Trials in Focus

Yahoo | November 9, 2023

Applied Therapeutics Reports Third Quarter 2023 Financial Results

Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol Dehydrogenase (SORD) Deficiency in 1Q 2024 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developin

Yahoo | November 9, 2023

Applied Therapeutics, Inc. (NASDAQ:APLT) is definitely on the radar of institutional investors who own 38% of the company

Key Insights Institutions' substantial holdings in Applied Therapeutics implies that they have significant influence...

Yahoo | November 5, 2023

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the UBS Biopharma Conference 2023 on Thursday, November 9, 2023 at 2:00 p.m. ET in Miami, Florida. A live webcast for this event will be accessible on the Events page under the Investor Relations section

Yahoo | November 2, 2023

Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7

Forum to be Webcast Live Topline Phase 3 Data Readout from ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy On Track for 4Q 2023 NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will host a Diabetic Cardiomyopathy (DbCM) expert forum with key opinion l

Yahoo | November 1, 2023

Read More 'APLT' Stories Here

APLT Price Returns

1-mo 2.11%
3-mo N/A
6-mo 64.63%
1-year 159.49%
3-year -88.29%
5-year N/A
YTD 218.42%
2022 -91.51%
2021 -59.34%
2020 -19.32%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!